Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0011 USD
Change Today 0.00 / 0.00%
Volume 0.0
RCLL On Other Exchanges
As of 4:30 PM 06/24/15 All times are local (Market data is delayed by at least 15 minutes).

regenocell therapeutics inc (RCLL) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/6/15 - $0.0045
52 Week Low
10/31/14 - $0.0008
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

regenocell therapeutics inc (RCLL) Related Businessweek News

No Related Businessweek News Found

regenocell therapeutics inc (RCLL) Details

RegenoCELL Therapeutics, Inc. manufactures and sells stem cell therapy products to treat congestive heart failure and peripheral artery disease. Its stem cells enable the normal development, and the regeneration and repair of damaged tissues through the ability to differentiate into the type of cell needed for growth or repair. The company intends to hold non exclusive license with TheraVitae, Inc. in Mexico and the Islands of the Caribbean to commercialize stem cell therapy for cardiovascular indications; and an exclusive license in the United States, Canada, and Mexico to obtain regulatory approvals and then market VesCell stem cell therapy for the treatment of peripheral artery disease. It also focuses on establishing clinics to treat congestive heart failure patients with VesCell stem cell therapy. The company was formerly known as Good Buddy's Coffee Express, Inc. and changed its name to RegenoCELL Therapeutics, Inc. in July 2008. RegenoCELL Therapeutics, Inc. was founded in 2002 and is headquartered in Natick, Massachusetts.

9 Employees
Last Reported Date: 05/25/12
Founded in 2002

regenocell therapeutics inc (RCLL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

regenocell therapeutics inc (RCLL) Key Developments

SEC Revokes Registration Of Registered Securities Of RegenoCELL Therapeutics

An Administrative Law Judge has issued an Initial Decision of Default as to RegenoCELL Therapeutics, Inc. The Initial Decision found that the company was issuer of securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act), and the company failed to comply with Section 13(a) of the Exchange Act and Exchange Act Rules 13a-1 and/or 13a-13 by not filing required periodic reports with the Securities and Exchange Commission (SEC). The Initial Decision finds these allegations to be true and revokes the registration of each class of the company’s registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.

SEC Orders Hearings On Registration Suspension Or Revocation Against RegenoCell Therapeutics For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of RegenoCell Therapeutics, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RCLL:US $0.00 USD 0.00

RCLL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RCLL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RCLL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENOCELL THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at